临床试验/NCT00984360

NCT00984360已完成2 期

A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP

California Pacific Medical Center Research Institute1 个研究点分布在 1 个国家目标入组 22 人开始时间: 2009年9月最近更新: 2013年5月31日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: California Pacific Medical Center Research Institute
入组人数: 22
试验地点: 1
主要终点: MA (-) Urine Samples

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to determine whether methamphetamine-dependent individuals will use less methamphetamine when treated with naltrexone. The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 50 Years（Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age between 18 and 50 years
•Patient is agreeable to conditions of study and signs consent form

排除标准

未提供

研究组 & 干预措施

A118G

Experimental

干预措施: Naltrexone (Drug)

Wild-type

Experimental

干预措施: Naltrexone (Drug)

结局指标

主要结局

MA (-) Urine Samples

时间窗: Twice weekly for 5 weeks

次要结局

未报告次要终点

研究者

发起方

California Pacific Medical Center Research Institute

申办方类型

Other

责任方

Principal Investigator

主要研究者

John Mendelson, MD

Senior Scientist

California Pacific Medical Center Research Institute

研究点 (1)

Loading locations...

相似试验

已完成

2 期

A Pilot Trial of Dextroamphetamine for Methamphetamine DependenceMethamphetamine Addiction

NCT00630682California Pacific Medical Center Research Institute60

已完成

4 期

Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.Alcohol Dependence

NCT00366626Medical University of South Carolina83

已完成

2 期

Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and DrinkingAlcohol Dependence

NCT00183222Medical University of South Carolina160

已完成

4 期

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced IllnessOpioid-Induced Constipation

NCT00672477Bausch Health Americas, Inc.237

Unknown

3 期

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care UnitOpioid-induced Constipation

NCT01050595St. John Health System, Michigan80